Catherine Bresson
Director, Operational Team, WIN Consortium
Executive committee
Razelle Kurzrock
Chief, Division of Hematology & Oncology, Sr. Deputy Center Director for Clinical Science, University of California San Diego Moores Cancer Center (USA)
Vladimir Lazar
Chief Scientific and Operating Officer, WIN Consortium
Brian Leyland-Jones
Vice President of Molecular and Experimental Medicine, Avera Cancer Institute (USA)
John Mendelsohn
Director, Khalifa Institute for Personalized Cancer Medicine and Past-President, the University of Texas MD Anderson Cancer Center (USA)
Amir Onn
Head, Institute of Pulmonary Oncology, The Chaim Sheba Medical Center (Israel)
Richard L. Schilsky
Chief Medical Officer, American Society of Clinical Oncology (ASCO); Chairman, WIN SAB
Josep Tabernero
Director and Clinical Research Director, Vall d'Hebron Institute of Oncology, VHIO (Spain)
Thomas Tursz
Chairman, Research Steering Committee, ARC Foundation (France)
Operational team
Catherine Bresson
Director, Operational Team, WIN Consortium
Layla El-Gharras
Consultant, Operational Team, WIN Consortium
Vladimir Lazar
Chief Scientific and Operating Officer, WIN Consortium
Eitan Rubin
Senior Lecturer, Ben-Gurion University of the Negev (Israel); Head, WIN IT Platform
Fanny Wunder
Project Manager, WIN Consortium
Scientific Advisory Board
Andrea Califano
Chair of Department of Systems Biology, Columbia University (USA); Vice Chairman of WIN SAB
Steve Anderson
Chief Scientific Officer, Covance, Inc. (USA)
Sung-Min Ahn
Associate Professor, Department of Hematology-Oncology, Gachon University Gil Medical Center (South Korea)
Phillip Febbo
Chief Medical Officer, Genomic Health
Stanley R. Hamilton
Head of Pathology & Laboratory Medicine Labs, The University of Texas, MD Anderson Cancer Center (USA)
Leroy Hood
President and Co-Founder, Institute for Systems Biology (USA)
Pasi A. Jänne
Scientific Director, Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute (USA)
J. Jack Lee
Associate Vice Provost for Quantitative Research, The University of Texas, MD Anderson Cancer Center (USA)
Yves Luisser
Associate Vice President for Health Sciences, The University of Arizona Cancer Center (USA)
Yudi Pawitan
Professor, Karolinska Institutet (Sweden)
John Quackenbush
Professor, Biostatistics & Computational Biology, Dana-Farber Cancer Institute (USA)
Gideon Rechavi
Head, Sheba Cancer Research Center, Chaim Sheba Medical Center (Israel)
Gary L. Rosner
Director, Division of Biostatistics and Bioinformatics, Department of Oncology, John Hopkins Medicine (USA)
Richard L. Schilsky
Chief Medical Officer, American Society of Clinical Oncology (ASCO); Chairman, WIN SAB
Lillian Siu
Staff Medical Oncologist, Princess Margaret Hospital (Canada)
Alan Spatz
Director, Department of Pathology & Professor of Pathology & Oncology, Jewish General Hospital & McGill University (Canada)
Yosef Yarden
Professor, Weizmann Institute of Science (Israel)
Directorate
George Wilding
Vice Provost, Clinical and Interdisciplinary Research, The University of Texas, MD Anderson Cancer Center (USA)
Frank Makosiej
Executive Director, Operational Strategy and Planning, Clinical Development Services, Covance, Inc.(USA)
Luis Eduardo Rosa Zucca
Medical Oncologist, Department of Clinical Oncology - Neoplasms Sector Genitourinary, Fundaçao Pio XII - Hospital de Câncer de Barretos (Brazil)
Alejandro Piris
Scientific Research Manager, Vall d'Hebron Institute of Oncology, VHIO (Spain)
Gerald Batist
Professor & Chair, Department of Oncology, McGill University and Director, Segal Cancer Center (Canada)
Marc Estève
General Director Hospital Group, Institut Curie (France)
Razelle Kurzrock
Chief, Division of Hematology & Oncology, Sr. Deputy Center Director for Clinical Science, University of California San Diego Moores Cancer Center (USA)
Ulrik Lassen
Professor, Head of Phase 1 Unit, Rigshospitalet (Denmark)
Brian Leyland-Jones
Vice President of Molecular and Experimental Medicine, Avera Cancer Institute (USA)
John Leite
Vice President, Oncology, Illumina (USA)
Jean-François Martini
Director, Translational Oncology, Pfizer, Inc. (USA)
Hilario Mata
Director of Global Academic Programs, The University of Texas, MD Anderson Cancer Center (USA)
Amir Onn
Head, Institute of Pulmonary Oncology, The Chaim Sheba Medical Center (Israel)
Angel Porgador
Associate Professor, Ben-Gurion University of the Negev (Israel)
Jacques Raynaud
President, Fondation ARC (France)
Eitan Rubin
Senior Lecturer, Ben-Gurion University of the Negev (Israel); Head, WIN IT Platform
Richard L. Schilsky
Chief Medical Officer, American Society of Clinical Oncology (ASCO); Chairman, WIN SAB
Alan Spatz
Director, Department of Pathology & Professor of Pathology & Oncology, Jewish General Hospital & McGill University (Canada)
Jennifer Stone
Market Development Manager, Oncology Business Unit, Illumina (USA)
Josep Tabernero
Director and Clinical Research Director, Vall d'Hebron Institute of Oncology, VHIO (Spain)
Ding-Wei Ye
Vice President International Affairs & Professor, Chairman of Department of Urology, Fudan University Shanghai Cancer Center (China)
Chang Sik Yu
President, Asan Medical Center Cancer Institute (South Korea)
General Assembly
Rui Manuel Reis
Coordinator, Molecular Oncology Research Center, Fundaçao Pio XII - Hospital de Câncer de Barretos (Brazil)
Marc Schlesser
Pneumologist, Pneumology Department, Centre Hospitalier de Luxembourg (Luxembourg)
Guy Berchem
Medical Oncologist,Centre Hospitalier de Luxembourg (Luxembourg)
Manju Sengar
Medical Oncologist and Officer in charge, Clinical Research Secretariat, ACTREC - Tata Memorial Center (India)
Isabelle Manneh-Vangramberen
Project Coordinator, European Cancer Patient Coalition - ECPC (Belgium)
Francesco De Lorenzo
President, European Cancer Patient Coalition - ECPC (Belgium)
Diana Coda-Forno Aguirre
Senior Medical Director, Covance, Inc. (USA)
Eric Raymond
Head of Medical Oncology, Groupe Hospitalier Paris Saint-Joseph (France)
George Wilding
Vice Provost, Clinical and Interdisciplinary Research, The University of Texas, MD Anderson Cancer Center (USA)
Frank Makosiej
Executive Director, Operational Strategy and Planning, Clinical Development Services, Covance, Inc.(USA)
Timothy Johnson
President and Chief Executive Officer, HTG Molecular (USA)
Catherine Larue
CEO, Luxembourg Institute of Health (Luxembourg)
Richard Kellner
Vice Chairman of the Board, SURVIVEiT®, (USA)
Matt Ellefson
Founder & CEO of SURVIVEiT®, (USA)
Luis Eduardo Rosa Zucca
Medical Oncologist, Department of Clinical Oncology - Neoplasms Sector Genitourinary, Fundaçao Pio XII - Hospital de Câncer de Barretos (Brazil)
Masashi Kanai
Associate Professor, Department of Clinical Oncology, Pharmacogenomics and Palliative Medicine, Graduate School of Medicine, Kyoto University Hospital (Japan)
Manabu Muto
Professor, Department of Therapeutic Oncology, Graduate School of Medicine, Head, Department of Clinical Oncology, Kyoto University Hospital (Japan)
Tamar Peretz-Yablonski
Head Department of Oncology, Hadassah Medical Center (Israel)
Alejandro Piris
Scientific Research Manager, Vall d'Hebron Institute of Oncology, VHIO (Spain)
Pierre Saintigny
Laboratory of Translational Research, Department of Translational Research and Innovation, Centre Léon Bérard (France)
Mohammad Afshar
CEO, Ariana Pharmaceuticals (France)
Amal Al Omari
Director, Office of Scientific Affairs and Research, King Hussein Cancer Center (Jordan)
Gerald Batist
Professor & Chair, Department of Oncology, McGill University and Director, Segal Cancer Center (Canada)
Raanan Berger
Director, Institute of Oncology, Sheba Medical Center (Israel)
Jean-Yves Blay
Professor of Medicine, Université Claude Bernard; Scientific Director, Canceropole Lyon Rhône Alpes, Centre Léon Bérard (France)
Rares Buiga
The Oncology Institute Ion Chiricuta (IOCN) (Romania)
Andrés Cervantes
Head of Section in Medical Oncology, INCLIVA (Spain)
Xi Cheng
Director, Office of International Affairs and Professor, Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center (China)
Anna Chioti
Operational Director of Department of Population Health, Luxembourg Institute of Health (Luxembourg)
Eun Kyung Cho
Department of Internal Medicine, Gachon University Gil Medical Center (South Korea)
Alexander Drilon
Physician, Thoracic Oncology Service and Developmental Therapeutics, Memorial Sloan-Kettering Cancer Center (USA)
Franck Dufour
Scientific Director, Fondation ARC (France)
Marc Estève
General Director Hospital Group, Institut Curie (France)
Trent Haywood
Chief Medical Officer, The Blue Cross and Blue Shield Association (USA)
Alexandru Irimie
The University of Medicine and Pharmacy Iuliu Haţieganu (Romania)
Tae Won Kim
Director, Clinical Research Center & Center for Personalized Cancer Medicine (Korea)
Oi Lian Kon
Senior Consultant & Head, Division of Medical Sciences, National Cancer Centre Singapore (Singapore)
Mariana Kuras
Chief Technology Officer, Ariana Pharmaceuticals (France)
Razelle Kurzrock
Chief, Division of Hematology & Oncology, Sr. Deputy Center Director for Clinical Science, University of California San Diego Moores Cancer Center (USA)
Ulrik Lassen
Professor, Head of Phase 1 Unit, Rigshospitalet (Denmark)
Vladimir Lazar
Chief Scientific and Operating Officer, WIN Consortium
Brian Leyland-Jones
Vice President of Molecular and Experimental Medicine, Avera Cancer Institute (USA)
John Leite
Vice President, Oncology, Illumina (USA)
Scott M. Lippman
Director, University of California San Diego Moores Cancer Center (USA)
Jean-François Martini
Director, Translational Oncology, Pfizer, Inc. (USA)
Hilario Mata
Director of Global Academic Programs, The University of Texas, MD Anderson Cancer Center (USA)
John Mendelsohn
Director, Khalifa Institute for Personalized Cancer Medicine and Past-President, the University of Texas MD Anderson Cancer Center (USA)
Hovav Nechushtan
Associate Professor, Oncology Department, Hadassah Hebrew University Medical School (Israel)
Benjamin Neel
Director, Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center (USA)
Finn Cilius Nielsen
Professor and Head, Genomic Medicine, Rigshospitalet (Denmark)
Amir Onn
Head, Institute of Pulmonary Oncology, The Chaim Sheba Medical Center (Israel)
Iman Osman
Associate Director, Cancer Institute, Director, Interdisciplinary Melanoma Program, New York University Langone Medical Center (USA)
Thierry Philip
Chairman of the Board of Directors, Institut Curie (France)
Angel Porgador
Associate Professor, Ben-Gurion University of the Negev (Israel)
C.S. Pramesh
Chief, Thoracic Surgery, Division of Surgical Oncology, ACTREC - Tata Memorial Center (India)
Jacques Raynaud
President, Fondation ARC (France)
Gloria Ribas
Researcher, INCLIVA (Spain)
Eitan Rubin
Senior Lecturer, Ben-Gurion University of the Negev (Israel); Head, WIN IT Platform
Dong Bok Shin
Department of Internal Medicine, Division of Hematology and Oncology, Gachon University Gil Medical Center (South Korea)
Lillian Siu
Staff Medical Oncologist, Princess Margaret Hospital (Canada)
Khee Chee Soo
Director, National Cancer Center of Singapore (Singapore)
Alan Spatz
Director, Department of Pathology & Professor of Pathology & Oncology, Jewish General Hospital & McGill University (Canada)
Jennifer Stone
Market Development Manager, Oncology Business Unit, Illumina (USA)
Josep Tabernero
Director and Clinical Research Director, Vall d'Hebron Institute of Oncology, VHIO (Spain)
Bin Tean Teh
Research Director, Institute for Molecular and Cellular Biology, National Cancer Center of Singapore (Singapore)
Christof von Kalle
Director, Department of Translational Oncology, NCT and DKFZ (Germany)
Casey Williams
Director of Molecular and Experimental Medicine, Avera Cancer Institute (USA)
John Wineman
Vice President, Business Development, HTG Molecular (USA)
Ding-Wei Ye
Vice President International Affairs & Professor, Chairman of Department of Urology, Fudan University Shanghai Cancer Center (China)
Chang Sik Yu
President, Asan Medical Center Cancer Institute (South Korea)